文献速递头颈部肿瘤放疗

碳离子放疗头颈部黏膜黑色素瘤多中心研究

Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-12-26

多因素分析显示肿瘤总容积和同步化疗是总生存的显著预后因素。碳离子放疗是头颈部黏膜黑色素瘤有前景的治疗选择。

要点

  • 碳离子放疗头颈部黏膜黑色素瘤2年总生存率69.4%、局部控制率83.9%。
  • 肿瘤总容积和同步化疗是总生存的显著预后因素。
  • 3级和4级晚期毒性分别为27例和7例,无5级晚期毒性。

核心结论

  • 碳离子放疗是头颈部黏膜黑色素瘤有前景的治疗选择。

研究设计与样本

  • 患者中位年龄68岁,男性111例、女性149例,均经组织学证实。

主要发现

  • 原发部位为鼻腔178例、鼻窦43例、口腔27例、咽部12例。
  • 中位随访22个月(范围1-132个月),2年总生存率69.4%、局部控制率83.9%。
  • 多因素分析显示肿瘤总容积和同步化疗是总生存的显著预后因素。

关键数值与推荐

  • 中位总剂量57.6 Gy RBE,中位16次。
  • 129例接受含达卡巴嗪的同步化疗。
  • 3级晚期毒性27例、4级晚期毒性7例(5例同侧失明、1例黏膜溃疡、1例照射野内第二原发肿瘤),无5级晚期毒性。

临床怎么用

  • 对于N0-1M0头颈部黏膜黑色素瘤,碳离子放疗可作为有前景的治疗选择。
  • 同步化疗和肿瘤总容积可作为总生存的预后参考因素。

局限性

  • 回顾性研究设计。
  • 中位随访仅22个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of carbon-ion radiation therapy (RT) for mucosal melanoma of the head and neck (MMHN) in the Japan Carbon-Ion Radiation Oncology Study Group study. METHODS AND MATERIALS: Patients with MMHN with N0-1M0 status who were treated with carbon-ion RT at 4 institutions in Japan between November 2003 and December 2014 were analyzed retrospectively. Two hundred sixty patients (male, 111; female, 149; median age, 68 years) with histologically proven MMHN were enrolled. RESULTS: Primary sites included the nasal cavity in 178 patients, paranasal sinuses in 43, oral cavity in 27, and pharynx in 12. Eighty-six patients had T3 tumors, 147 had T4a tumors, and 27 had T4b tumors. Two hundred fifty-one patients were diagnosed with N0 disease, and 9 with N1 disease. The median total dose and number of fractions were 57.6 Gy RBE (relative biological effectiveness) and 16, respectively. Chemotherapy including dimethyl traizeno imidazole carboxamide was used concurrently in 129 patients. The median follow-up duration was 22 months (range, 1-132 months). The 2-year overall survival and local control rates were 69.4% and 83.9%, respectively. Multivariate analysis showed that gross tumor volume and concurrent chemotherapy were significant prognostic factors for overall survival. Grade 3 and grade 4 late morbidities were observed in 27 and 7 patients (5 developed ipsilateral blindness, 1 mucosal ulcer, and 1 second malignant disease in the irradiated volume), respectively. No patients developed grade 5 late morbidities. CONCLUSION: Carbon-ion RT is a promising treatment option for MMHN.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Koto M, Demizu Y, Saitoh JI, et al. Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys. 2016. PMID: 28332989. doi:10.1016/j.ijrobp.2016.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。